Ddx5 and ddx17 are two highly related RNA helicases involved in both transcription and splicing. These proteins coactivate transcription factors involved in cancer such as the estrogen receptor alpha, p53 and beta-catenin. Ddx5 and ddx17 are part of the splicing machinery and can modulate alternative splicing, the main mechanism increasing the proteome diversity. Alternative splicing also has a role in gene expression level regulation when it is coupled to the nonsensemediated mRNA decay (NMD) pathway. In this work, we report that ddx5 and ddx17 have a dual role in the control of the pro-migratory NFAT5 transcription factor. First, ddx5 and ddx17 act as transcriptional coactivators of NFAT5 and are required for activating NFAT5 target genes involved in tumor cell migration. Second, at the splicing level, ddx5 and ddx17 increase the inclusion of NFAT5 exon 5. As exon 5 contains a pre-mature translation termination codon, its inclusion leads to the regulation of NFAT5 mRNAs by the NMD pathway and to a decrease in NFAT5 protein level. Therefore, we demonstrated for the first time that a transcriptional coregulator can simultaneously regulate the transcriptional activity and alternative splicing of a transcription factor. This dual regulation, where ddx5 and ddx17 enhance the transcriptional activity of NFAT5 although reducing its protein expression level, suggests a critical role for ddx5 and ddx17 in tumor cell migration through the fine regulation of NFAT5 pathway.
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Introduction
Breast cancer is a leading cause of morbidity in women worldwide because of metastasis formation, which is directly linked to the migratory and invasive phenotype of cancer cells (Friedl and Wolf, 2003) . Invasion is a complex process relying on the capacity of the cells to migrate and to destroy and reorganize the extracellular matrix. It is now well established that tumor progression relies on the alteration of transcriptional programs controlling specific cellular programs (Hanahan and Weinberg, 2000) . In this context, the NFAT family of transcription factors is gaining increasing interest in breast cancer. This family comprises five genes, NFAT1 to NFAT5. NFAT1, NFAT2, NFAT3 and NFAT4 have been first identified as T-cell transcription factors, whereas NFAT5 has been involved in the cellular response to osmotic stress (Macian, 2005; Burg et al., 2007; Mancini and Toker, 2009; Muller and Rao, 2010) . It is now well documented that NFAT proteins are also present in non-immune cells and regulate a variety of signaling pathways involved in cell growth and development (Baksh et al., 2002; Chuvpilo et al., 2002; Mancini and Toker, 2009; Muller and Rao, 2010) . Importantly, members of the NFAT family, in particular NFAT5, have recently been involved in the migratory capacity of breast cancer cells (Jauliac et al., 2002; Ayers et al., 2004; Yoeli-Lerner et al., 2005; Mancini and Toker, 2009; Fougere et al., 2010; Muller and Rao, 2010) .
Increasing evidences indicate that alterations of splicing programs contribute to tumor progression (Blencowe, 2003; David and Manley, 2010; Warzecha et al., 2010; Dutertre et al., 2010b) . Indeed, most of the human genes can generate different splicing variants coding for different protein isoforms having slightly different activities or even opposite biological activities (Stamm et al., 2005; David and Manley, 2010; Dutertre et al., 2010b) . In addition, alternative splicing can have an important role in the regulation of gene expression level. Indeed, about one third of alternative exons contain a pre-mature translation termination codon resulting in mRNA regulation by the nonsensemediated mRNA decay (NMD) pathway. Therefore, the coupling of alternative splicing with NMD may provide a general means of decreasing protein expression level. This mechanism that has been referred to as 'regulated unproductive splicing and translation' or RUST has been involved in the downregulation of several cancer-related proteins (Lewis et al., 2003; Barbier et al., 2007; Chang et al., 2007; Neu-Yilik and Kulozik, 2008; Gardner, 2010) .
Although transcriptional programs are under the control of transcriptional factors and coregulators, splicing programs are under the control of splicing factors (Blencowe, 2003; David and Manley, 2010; Warzecha et al., 2010; Dutertre et al., 2010b ). An increasing number of proteins have been involved in both transcription and splicing (Auboeuf et al., 2007; Allemand et al., 2008) . This is the case of the highly related ddx5 and ddx17 RNA helicases (also known as p68 and p72, respectively) that act both in transcription and splicing. Indeed, ddx5 and ddx17 are transcriptional coregulators of the estrogen receptor alpha, p53, betacatenin and MyoD transcription factors among others (Watanabe et al., 2001; Bates et al., 2005; Caretti et al., 2006; Fuller-Pace and Ali, 2008) . It is believed that ddx5 and ddx17 are recruited on target gene promoters by these transcriptional factors and in turn recruit the RNA polymerase II or enzymes with histone acetylase or deacetylase activities (Metivier et al., 2003; Rossow and Janknecht, 2003; Wilson et al., 2004; Janknecht, 2010; Dutertre et al., 2010a; Fuller-Pace and Moore, 2011) . In addition, ddx5 and ddx17 copurify with the splicing machinery or spliceosome and can change alternative splicing-site selection in transcripts produced from the H-ras, CD44 and Tau genes Honig et al., 2002; Guil et al., 2003; Camats et al., 2008; Clark et al., 2008; Kar et al., 2011) . There are now many reports indicating that these multifunctional proteins have important implications for cancer development, as recently reviewed (Janknecht, 2010; FullerPace and Moore, 2011) . For example, on one hand, as transcriptional coactivators of estrogen receptor alpha, they may contribute to the proliferative effect of estradiol on breast cancer cells (Wortham et al., 2009; Dutertre et al., 2010a) and, as coregulators of betacatenin, they may contribute to the epithelial to mesenchymal transition, which has been associated with breast cancer progression (Yang et al., 2006) . On the other hand, as coactivators of p53 and Smad, ddx5/ ddx17 may exert tumor suppressor functions (Warner et al., 2004; Bates et al., 2005) . However, oncogenic functions or tumor suppressor roles of ddx5 and ddx17 are still a matter of debate and could be contextdependent (Fuller-Pace and Moore, 2011) .
In this work, we report that ddx5 and ddx17 have a dual role in the control of the pro-migratory NFAT5 transcription factor. First, ddx5 and ddx17 act as transcriptional coactivators of NFAT5 and are required for activating NFAT5 target genes involved in tumor cell migration. Second, at the splicing level, ddx5 and ddx17 favor the inclusion of the human NFAT5 exon 5 that contains a pre-mature translation termination codon, which then results in the synthesis of the unproductive (that is, not translated) NFAT5 mRNAs and in the reduction of the NFAT5 protein level. This dual activity of ddx5 and ddx17 may have a role in the fine regulation of the NFAT5 pathway and may contribute to the context-dependent role of ddx5 and ddx17 in cancer.
Results
Ddx5 and ddx17 are required for mediating the promigratory effect of NFAT5 Ddx5 and ddx17 have been reported to be transcriptional coactivators of several key transcriptional factors, including estrogen receptor alpha, p53 and beta-catenin and are likely to have a role in tumor initiation and/or progression (Janknecht, 2010; Fuller-Pace and Moore, 2011) . As ddx17 has been co-purified with NFAT5 (Chen et al., 2007) , we tested whether ddx17 and its paralog, ddx5, co-immunoprecipitate with NFAT5 in human MDA-MB-231 breast cancer cells. As shown on Figure 1a (left panel), FLAG-ddx17 protein was specifically detected after the immunoprecipitation of a Myc-NFAT5 protein. Conversely, Myc-NFAT5 protein was specifically detected after the immunoprecipitation of FLAG-ddx17 (right panel, Figure 1a ). Likewise, Myc-NFAT5 protein was detected after the immunoprecipitation of endogenous ddx5 protein (left panel, Figure 1b ) or after the immunoprecipitation of a HAddx5 protein (right panel, Figure 1b ). Finally, immunoprecipitation of the endogenous NFAT5 protein, coimmunoprecipitate the endogenous ddx5 protein but not when cells were first transfected with a siRNA targeting NFAT5 (Figure 1c) .
Because we could not immunoprecipitate endogenous ddx17 with endogenous NFAT5 protein, the ability of endogenous NFAT5 protein to associate with endogenous ddx17 and ddx5 proteins was further assessed with the in situ proximity ligation assay (PLA), which generates a signal when two proteins are in close proximity (B40 nm) to each other. As shown on Figure 1d , prominent signals were detected in fixed MDA-MB-231 cells between anti-NFAT5 and anti-ddx5, and anti-NFAT5 and antiddx17 antibodies but not in control experiments. Numbers of signals were on average of 14 per cells after incubation of anti-NFAT5 and anti-ddx5 antibodies, and of 11 per cells after incubation of anti-NFAT5 and anti-ddx17 antibodies (Figure 1e) . Moreover, the number of signals markedly decreased in MDA-MB-231 cells after transfection with siRNAs targeting either NFAT5 or both ddx5 and dd17 (Figure 1f ).
In addition, the over-expression of ddx5 and ddx17 enhanced the transcriptional activity of NFAT5 as measured using a luciferase reporter gene driven by an NFAT5-responsive promoter suggesting that ddx5 and ddx17 are NFAT5 transcriptional co-activators (Figure 1g ). To test further this hypothesis, we next analyzed the effect of ddx5 and ddx17 on NFAT5 promigratory function.
Indeed, it has been shown that NFAT5 is a transcriptional factor that stimulates cell migration (Jauliac et al., 2002; O'Connor et al., 2007) . As expected, NFAT5 over-expression in MDA-MB-231 cells increased cell migration (Figure 2a ), whereas NFAT5 depletion decreased it (Figure 2b ). The depletion of either ddx5 or ddx17 had almost no effect on cell migration (Figure 2c) . However, the depletion of either ddx5 or ddx17 further inhibited cell migration mediated by the decrease in NFAT5 expression level (Figure 2d , Supplementary Figure S1 ). In addition, the depletion of both ddx5 and ddx17 strongly decreased cell migration ( Figure 2e ) and, finally, NFAT5 depletion did not inhibit cell migration in the absence of ddx5 and ddx17 (comparing lane 2 to lane 4, Supplementary Figure S2 ).
Collectively, these results suggest that ddx5 and ddx17 have a role in cell migration by co-activating NFAT5. To further test this hypothesis, the ddx5 and ddx17 effect on NFAT5 endogenous target genes was next investigated. 
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Regulation of NFAT5 by ddx5/ddx17 S Germann et al It has been reported that NFAT5 regulates the transcriptional activity of the S100A4 gene in a direct manner (Chen et al., 2009 . S100A4 or metastasin, which is a member of the S100 family of calcium-binding proteins, has been shown to have an important role in breast cancer progression (Helfman et al., 2005; Garrett Regulation of NFAT5 by ddx5/ddx17 S Germann et al et al., 2006) . We have recently reported that lipocalin 2 (LCN2), which also plays a role in breast cancer progression (Yang et al., 2009; Leng et al., 2011) , is regulated by NFAT transcriptional factors (Fougere et al., 2010) . As expected, the depletion of NFAT5 decreased the S100A4 and LCN2 mRNA levels ( Figure 3a ). In addition, chromatin immunoprecipitation (ChIP) assay using NFAT5 antibody indicated that NFAT5 was bound to the S100A4 and LCN2 promoters (Figure 3b , Supplementary Figure S3 ), as expected (Chen et al., 2009) .
We next tested the role of ddx5 and ddx17 on the regulation of S100A4 and LCN2 genes. The depletion of both ddx5 and ddx17 decreased the S100A4 and LCN2 mRNA levels ( Figure 3c ). Furthermore, the sub-optimal depletion of NFAT5 together with ddx5 and ddx17 showed an additive effect ( Figure 3d , Supplementary Figure S1 ). To test whether the observed effects were direct transcriptional effects, ChIP assay was performed after MDA-MB-231 transfection with either HA-ddx5 or FLAG-ddx17 expression vectors. Both ddx5 and ddx17 specifically bound to the S100A4 and LCN2 promoters and, importantly, NFAT5 depletion reduced their recruitment (Figures 3e and f). Together with the interaction and transactivation studies (Figure 1 ), these results demonstrate that ddx5 and ddx17 are bona fide transcriptional coactivators of the NFAT5 pro-migratory transcriptional factor.
Ddx5 and ddx17 regulate alternative splicing of the NFAT5 gene We tested whether the effects of ddx5/ddx17 depletion on cell migration and gene expression might be due to a decrease in NFAT5 protein level. Remarkably, ddx5/ ddx17 depletion in MDA-MB-231 cells did not decrease NFAT5 protein level, but instead strongly increased it (left panel, Figure 4a ). Similar results were obtained in the human MCF-7 breast cancer cells (right panel, Figure 4a ) and in the human HeLa cells (see below). We demonstrated that the protein detected by immunoblot with the NFAT5 antibody after ddx5/ddx17 depletion was indeed NFAT5, by co-transfecting MDA-MB-231 cells with an siRNA targeting NFAT5 (Figure 4b) . Therefore, the effects described above of ddx5/ddx17 depletion on migration and NFAT5 target genes are clearly not explained by a decrease in NFAT5 protein level. In fact, the inhibition of NFAT5 target genes expression resulting from ddx5/ddx17 depletion (Figure 3) despite the increase in NFAT5 protein level in these conditions (Figure 4a ) is probably due to the requirement of ddx5 and ddx17 in mediating NFAT5 transcriptional effects (Figures 1 and 3) .
We next analyzed the mechanisms by which ddx5 and ddx17 control NFAT5 expression level. Remarkably, the depletion of ddx5 and ddx17 did not affect the total NFAT5 mRNA level in any of the tested cell lines (Figure 4c ). However, RT-PCR using primers in exons 3 and 6 that flank known alternative exons 4 and 5 (Dalski et al., 2002; Maouyo et al., 2002) revealed that ddx5/ ddx17 depletion in MDA-MB-231, HeLa and MCF-7 cells favored the shorter NFAT5 product that did not contain exons 4 and 5 (E3/E6, Figure 4d ). This result was further supported after sequencing the PCR products (not shown) and by quantifying NFAT5 splicing variants by RT-Quantitative (q)PCR. As expected from PCR results (Figure 4d ), ddx5/ddx17 depletion increased the splicing variants lacking exons 4 and 5 (E3/E6, Figure 4e) , whereas decreasing the level of the splicing variants containing exon 5 (E5/E6, Figure 4e ). The level of the splicing variants containing exon 4 but not exon 5 (E4/E6) was not affected in HeLa and MCF-7 cells and increased in the MDA-MB-231 cells (E4/E6, Figure 4e ).
These results indicated that ddx5/ddx17 depletion induced the skipping of exon 5 and this was confirmed by using primers that allowed to specifically quantify each splicing variant containing or not exon 5. Indeed, the level of exon 5 containing transcripts decreased after ddx5/ddx17 depletion when compared with the level of transcripts that did not contain exon 5, either in the presence or in the absence of exon 4 (Figure 4f ).
These data suggested that ddx5/ddx17 depletion impacts on alternative splicing of the human NFAT5 exon 5. This possibility was first confirmed by using another set of siRNAs targeting the UTRs of ddx5 or ddx17 (siUTRddx5/17) that indeed increased the level of NFAT5 splicing variants that did not contain exon 5 in HeLa cells (E3/E6 vs E5/E6 and E4/E6 vs E5/E6, Figure 5a ). In addition, cell co-transfection with wildtype ddx5 or ddx17 cDNAs that do not contain UTR sequences and that are therefore not affected by siUTRddx5/17, partially rescued the siUTRddx5/17 effect on NFAT5 splicing (Figure 5a ). Importantly, mutated ddx5 and ddx17 cDNAs encoding proteins lacking the helicase activity did not rescue the splicing phenotype (Figure 5a ). Furthermore, ddx5 and ddx17 depletion resulted in a strong increase in NFAT5 protein expression level in HeLa cells (Figure 5b Going a step forward, we next tested whether ddx5 and/or ddx17 immunoprecipate the NFAT5 premRNA. HeLa cells were transfected either with HAddx5 or FLAG-ddx17 expression vectors or with the corresponding empty expression vectors as controls that did not affect NFAT5 pre-mRNA level (IN, Figure 5c ). After formaldehyde-mediated crosslinking of HeLa cells, HA and FLAG antibodies immunoprecipitated NFAT5 pre-mRNA in the HA-ddx5-and FLAGddx17-transfected cells, respectively, but not in the control cells (Figure 5c ). Similar results were obtained using inducible stable MCF-7 cells expressing HA-ddx5 or FLAG-ddx17 proteins (Figure 5d ).
To further test the potential role of ddx5 and ddx17 in NFAT5 alternative splicing, a minigene containing the human NFAT5 exon 5 and about 200 nucleotides of the surrounding introns was generated ( Figure 5e ). As expected, ddx5/ddx17 depletion in HeLa cells induced the skipping of the minigene exon 5 (Figure 5e ). Furthermore, the over-expression of wild-type but not mutated ddx5 and ddx17 proteins in HeLa cells antagonized the splicing effect of ddx5/ddx17 depletion Regulation of NFAT5 by ddx5/ddx17 S Germann et al (Figure 5f ). Similarly, the over-expression of wild-type ddx5 or ddx17 in MDA-MB-231 cells favored exon 5 inclusion in the minigene assay, whereas the overexpression of mutated ddx5 or ddx17 form induced exon 5 skipping (Figure 5g) . Collectively, these results demonstrated that ddx5 and ddx17 favor NFAT5 exon 5 inclusion in an RNA helicase activity-dependent manner.
NFAT5 protein level is regulated by splicing coupled to NMD On analyzing NFAT5 sequence, we observed that NFAT5 exon 5 contains two in-frame stop codons that are conserved during evolution (Figure 6a ). This suggested that NFAT5 transcripts containing this exon might be unproductive (that is, not-translated) transcripts and regulated by the NMD pathway. To test this hypothesis, MDA-MB-231 and HeLa cells were treated for 4 and 6 h with the translation inhibitor cycloheximide, which inhibits mRNA degradation by the NMD pathway that requires on-going translation. As shown on Figure 6b , cycloheximide treatment increased the level of the NFAT5 splicing variants containing exon 5 (E5/E6, Figure 6b) . Therefore, the ratio of transcripts containing exon 5 to transcripts that do not contain exon 5 was increased by cycloheximide treatment in both MDA-MB-231 and HeLa cells (Figure 6c ). Similarly, cell transfection with a siRNA targeting RT-PCR analysis of NFAT5 transcripts using a forward primer in exon 3 and a reverse primer in exon 6 in the same experimental conditions as in panel C. (e) RT-qPCR analysis of NFAT5 transcripts, in the same experimental conditions as in panel C, using primers to amplify transcripts containing exon 5 (E5/E6), neither exon 5 nor exon 4 (E3/E6) or exon 4 alone (E4/E6). (f) RTqPCR analysis of NFAT5 transcripts, in the same experimental conditions as in panel C, using primers to amplify transcripts containing exons 3, 4, 5 and 6 (E3/E4/E5/E6), transcripts containing exons 3, 4 and 6 (E3/E4/E6), transcripts containing exons 3, 5 and 6 (E3/E5/E6), or transcripts containing exons 3 and 6 only (E3/E6). Histograms represent the average of at least three independent experiments and represent the fold effect of the siRNA targeting ddx5 and ddx17 compared with a control siRNA. Error bars represent s.e.m. (*Po0.05, **Po0.01, ***Po0.001).
Regulation of NFAT5 by ddx5/ddx17
S Germann et al UPF1, a major actor of the NMD pathway, increased by B20 to 50% the ratio of transcripts containing exon 5 to transcripts that do not contain exon 5 in MDA-MB-231 cells (MDA-MB-231, Figure 6d ). A stronger increase by B100% was observed in HeLa cells (HeLa, Figure 6d ). Therefore, the data described on Figures 5 and 6 indicated that the regulation by ddx5 and ddx17 of NFAT5 exon 5 inclusion coupled with NMD provides a means for regulating NFAT5 protein expression level.
To further test this model, siRNAs targeting either all NFAT5 splicing variants (siN5 targeting sequences in exons 7 and 9) or specifically the splicing variants containing human exon 5 (siE5) were generated. As expected, cell transfection with siN5 or siE5 decreased the global level of all NFAT5 transcripts (Total, Figure 6e ) and the level of the splicing variants containing E5 (E5/E6, Figure 6e ). As expected, siE5 did not affect the level of the transcripts that do not contain exon 5 in contrast to siN5 (E3/E6, Figure 6e ), which demonstrated the specificity of the siE5 siRNA. More importantly, siN5, but not siE5, strongly decreased the NFAT5 protein level (Figure 6f ). This result indicated that NFAT5 transcripts containing exon 5 did not significantly contribute to NFAT5 protein synthesis. This result was confirmed by using an other siRNA targeting NFAT5 exon 2 (siE2) that has also been shown to be alternatively spliced (Dalski et al., 2002) . Indeed, although siE2 had a similar effect to siE5 on the global NFAT5 mRNA level (Total, Figure 6e ), siE2 but not siE5 decreased NFAT5 protein level (Figure 6g) . Collectively, these results demonstrated that ddx5 and ddx17 decreased NFAT5 protein level by favoring exon 5 inclusion, which resulted in the synthesis of unproductive (that is, not translated) mRNAs.
Discussion
Ddx5 and ddx17 are two highly related RNA helicases that have been involved in several steps of the gene expression process (Fuller-Pace and Ali, 2008; Janknecht, 2010). In particular, ddx5 and ddx17 act as transcriptional coregulators of transcription factors like estrogen receptor alpha, p53 and beta-catenin that have important roles in cancer initiation and progression. Although the role of ddx5 and ddx17 in cancer cell proliferation has been reported, our data identified a role for ddx5/ddx17 in cell migration (Figure 2 ). This new function of ddx5 and ddx17 is likely to be mediated, at least in part, by the regulation of the expression of the S100A4 and LCN2 genes that are involved in tumor progression and that are target genes of the NFAT5 transcription factor (Figures 1  and 3) , which itself is known to favor cell migration (Jauliac et al., 2002) .
Indeed, it has been shown that, in breast cancer, intracellular S100A4 can induce cell motility in part through its ability to interact with myosin-IIA and extracellular S100A4 can stimulate MMP-13 activity, possibly contributing to tumor invasion (Garrett et al., 2006; Li and Bresnick, 2006) . Therefore, S100A4 can promote metastasis and crossing mice that overexpress S100A4 in the mammary epithelium with mouse models of metastasis dramatically increases the incidence of metastasis (Davies et al., 1996) . Finally, S100A4 expression is associated with a metastatic phenotype in multiple types of carcinoma, including breast cancer (Garrett et al., 2006) . Similarly, elevated levels of LCN2 expression have been reported in various cancers, including breast cancer. Remarkably, there is a strong association between LCN2 and metastasis (Yang et al., 2009) . LCN2 is a member of the lipocalin family composed of small extracellular proteins that transport and present ligands to cell surface receptors, and form macromolecular complexes, thus playing important roles in cell regulation, proliferation and differentiation (Flower, 1994) . LCN2 can enhance tumor growth and metastasis by protecting matrix metalloproteinase-9 from degradation and by increasing angiogenesis and/ or by promoting the epithelial to mesenchymal transition, which is associated with breast cancer progression (Leng et al., 2009; Yang et al., 2009) . Therefore, this study identified a novel gene regulatory pathway (NFAT5 stimulation of S100A4 and LCN2 genes) that is coactivated by ddx5/ddx17 and that, together with previously reported ddx5 and ddx17 target genes like cyclin D1 and Snail (Shin et al., 2007; Yang et al., 2007; Carter et al., 2010) , strengthens the role of ddx5 and ddx17 in tumor progression.
We also demonstrated that ddx5 and ddx17 regulate NFAT5 pre-mRNA splicing in addition to acting as NFAT5 transcriptional coactivators. Indeed, ddx5 and ddx17 splicing activity, relying on their helicase activity, favored the inclusion of the human NFAT5 exon 5 (Figures 4 and 5) . To the best of our knowledge, this is the first demonstration that a transcriptional coregulator modulating the activity of a transcriptional factor can also control its expression at the splicing level. It must be underlined that ddx5, that coactivates p53, has been shown to selectively regulate the expression of the delta133p53 isoform (Moore et al., 2010) . However, this isoform is not generated by alternative splicing but by transcription from an internal promoter in intron 4 of the p53 gene. Remarkably, the effect of ddx5 and ddx17 on NFAT5 splicing has a very important role in NFAT5 protein expression level. Indeed, ddx5 and ddx17 favored the inclusion of the NFAT5 exon 5, which generated unproductive transcripts that were not translated ( Figure 6 ). Interestingly NFAT5 exon 5 is one of the 111 'ultraconserved elements' identified in human protein-coding genes (Bejerano et al., 2004; McGlincy and Smith, 2008) . It has been reported that many ultraconserved elements are associated with exons inducing NMD ( (Bejerano et al., 2004; McGlincy and Smith, 2008) . In this context, the ddx5/ddx17 effect on NFAT5 expression was observed in different human cell lines (Figure 4) as well as in a mouse cell line (Supplementary Figure S4) . Collectively, these observations strengthen the key role of exon 5 in NFAT5 gene expression regulation. However, we cannot exclude that, Regulation of NFAT5 by ddx5/ddx17 S Germann et al in some cellular contexts, the NFAT5 mRNA bearing exon 5 may escape NMD. However, many reports have indicated that NFAT5 protein level is tightly regulated, particularly during differentiation and in response to hyper-osmotic stresses (Woo et al., 2000; Ferraris et al., 2002) . It has been shown that NFAT5 protein level is regulated by several mechanisms involving protein stability and miRNA-mediated mRNA silencing (Dahl et al., 2001; Irarrazabal et al., 2010; Levy et al., 2010) . We now report that NFAT5 protein level can also be regulated by the coupling of splicing to the NMD pathway (Figures 4, 5 and 6 ). It will be interesting to test whether this ddx5/ddx17-dependent mechanism is involved in NFAT5 protein level regulation in hyperosmotic conditions. Similarly, NFAT5 protein level is regulated during development and NFAT5 has a role in muscle differentiation (O'Connor et al., 2007) . As ddx5 and ddx17 also have a role in muscle differentiation (Caretti et al., 2006) , it will be interesting to test the interplay between NFAT5 and ddx5/ddx17 in muscle development.
In conclusion, our data indicate that, on one hand, ddx5 and ddx17 transcriptional activity enhances NFAT5-mediated effects and, on the other hand, ddx5-and ddx17-splicing activity decreases NFAT5 protein level. These dual functions of ddx5 and ddx17 
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Regulation of NFAT5 by ddx5/ddx17 S Germann et al RT-qPCR analysis of NFAT5 transcripts after 6 h of cycloheximide treatment using primers to amplify transcripts containing exons 3, 4, 5 and 6 (E3/E4/E5/E6), transcripts containing exons 3, 4 and 6 (E3/E4/E6), transcripts containing exons 3, 5,and 6 (E3/E5/E6), or transcripts containing exons 3 and 6 (E3/E6). (d) RT-PCR using UPF1 specific primers (upper panel) and RT-qPCR (lower panel) as described in panel C after transfection of MDA-MB-231 and HeLa cells with a control siRNA (siCTRL) or a siRNA targeting UPF1 (siUPF1). Data are represented as % of increase measured in three independent experiments. (e) RT-qPCR analysis of all NFAT5 mRNAs (Total), splicing variants containing none of exon 4 and exon 5 (E3/E6), splicing variants containing exon 2 (E1/E2) or exon 5 (E5/E6) after transfection of MDA-MB-231 cells with a control siRNA, siN5 targeting all NFAT5 splicing variants, siE2 targeting the NFAT5 splicing variants containing exon 2 or siE5 targeting the NFAT5 splicing variants containing exon 5. (f) WB analysis of NFAT5 and actin 48 h after transfection of MDA-MB-231 cells with a control siRNA (siCTRL), siN5 or siE5. (g) WB analysis of NFAT5 and actin 48 h after transfection of MDA-MB-231 cells with a control siRNA (siCTRL), siN5, siE2 or siE5. WBs and PCR gels are representative of at least three independent experiments. Histograms represent the average of at least three independent experiments. Error bars represent s.e.m. (*Po0.05, **Po0.01, ***Po0.001). Figure 5 Regulation of NFAT5 alternative splicing by ddx5 and ddx17. (a) WB analysis of ddx5 and ddx17 after transfection of HeLa cells with a control siRNA or siRNAs targeting ddx5 or ddx17 UTRs (siUTRddx5/17) together with control expression vectors or wildtype ddx5 (ddx5 WT), wild-type ddx17 (ddx17 WT), mutated ddx5 (ddx5 MUT), or mutated ddx17 (ddx17 MUT) expression vectors (upper panel). Tagged ddx5 protein is marked by an asterisk. RT-qPCR analysis of NFAT5 transcripts, in the same experimental conditions as described above, using primers to amplify transcripts containing exon 5 (E5/E6), none of exon 5 and exon 4 (E3/E6) or exon 4 alone (E4/E6). Histograms represent the average of the E3/E6 to E5/E6 ratio and the E4/E6 to E5/E6 ratio obtained in three independent experiments. (b) WB analysis of NFAT5, ddx5, ddx17 and actin, 48 h after transfection of HeLa cells with a control siRNA or siRNAs targeting ddx5 or ddx17 UTRs (siUTRddx5/17) together with control expression vectors or wild-type ddx5 or ddx17 expression vectors. (c) RT-PCR and RT-qPCR analysis of NFAT5 pre-mRNAs precipitated using HA or FLAG antibodies after transfection of HeLa cells with HA-ddx5, FLAG-ddx17 or empty expression vectors. Histograms correspond to the average level of precipitated NFAT5 pre-mRNA compared with the input obtained in three independent experiments. (d) WB analysis of HA-ddx5 and Flag-ddx17 in the presence or absence of doxycycline using inducible MCF-7/Tet-On stable cell lines. RT-qPCR analysis of NFAT5 pre-mRNAs precipitated using HA, FLAG or control (IgG) antibodies after induction by doxycycline (dox) of HA-ddx5 or FLAG-ddx17 expression in stable MCF-7 cell lines. Histograms correspond to the average level of precipitated NFAT5 pre-mRNA compared with the input obtained in three independent experiments. Regulation of NFAT5 by ddx5/ddx17 S Germann et al probably have an important role that is conserved during evolution in the NFAT5 pathway (Supplementary Figure S4 ). Increasing the level of ddx5/ddx17 would enhance NFAT5-mediated pro-migratory effects and would be antagonized by a decrease in NFAT5 protein level mediated by ddx5-and ddx17-splicing activity. Meanwhile, decreasing the level of ddx5/ ddx17 would increase NFAT5 protein level but repress the expression level of ddx5/ddx17-dependent NFAT5 target genes like S100A4 and LCN2. Interestingly, all NFAT5 target genes might not be ddx5/ddx17-dependant genes. Indeed, among the tested NFAT5 target genes, we observed that the SMIT (sodium/myo-inositol cotransporter) gene, a known NFAT5 target gene was downregulated after NFAT5 depletion, but upregulated after ddx5/17 depletion, likely owing to the increase in NFAT5 protein level (Supplementary Figure S5) . Even though the interplay between ddx5/ddx17 and the NFAT5-signaling pathway is likely complex, ddx5 and ddx17 seem to have a critical role in the regulation of a subset of NFAT5 target genes involved in cell migration as ddx5/ddx17 depletion inhibited this process (Figure 2 ). The precise and respective role of ddx5 and ddx17 in the NFAT5 pathway will also require further experiments. Indeed, we systematically observed that the co-depletion of ddx5 and ddx17 had a stronger effect on NFAT5 pathway and NFAT5 gene expression regulation than the depletion of either ddx5 or ddx17 alone (Figure 2 ; Supplementary Figures S6 and S7 ). Even though these results suggest that ddx5 and ddx17 have similar activities, the data obtained could be explained either by ddx5 and ddx17 having full redundant functions when co-expressed in cells (meaning that they work together in the same complexes) or by their replacement by each other when one or the other is missing.
Finally, it is interesting to integrate the dual impact of ddx5 and ddx17 on the pro-migratory NFAT5 transcription factor in the context of the known role of ddx5 and ddx17 in cancer. Indeed, although there are increasing evidences that these proteins have an important role in cancer, their effects are likely to be context-dependent, as recently reviewed (Fuller-Pace and Moore, 2011) . Ddx5 and ddx17 have been reported to have either oncogenic functions or tumor cosupressor roles (Fuller-Pace and Moore, 2011) . One intriguing possibility is that, depending on the cellular context, ddx5/ddx17-splicing activity or their transcriptional activity could dominate each other and this could participate in the dual function of ddx5 and ddx17 in cancer. In this context, several reports have indicated that the splicing and transcriptional activities of ddx5 and ddx17 can be modulated by different post-translational modifications that depend on cellular signaling pathways (Yang et al., 2006 (Yang et al., , 2007 Jacobs et al., 2007; Carter et al., 2010; Mooney et al., 2010a, b) . In addition, several post-translational modifications of ddx5 or ddx17 have been shown to be altered in different cancers (Causevic et al., 2001; Yang et al., 2005) . Therefore, different cellular signaling pathways activated in different cellular contexts may favor one of the molecular functions of ddx5 and ddx17, which could have different impact on cell behavior and tumor progression.
Materials and methods
Cell culture, plasmid constructions and stable cell lines Cells were maintained in DMEM supplemented with 10% fetal bovine serum, 1% glutamine, 1% penicillin and streptomycin antibiotics and 4,5 g/l glucose (HeLa, MCF-7) or 1 g/l glucose (MDA-MB-231). HA-ddx5 and FLAG-ddx17 were cloned in pTRE2-hyg vector to generate inducible MCF-7/Tet-On stable cell lines (Clontech, Saint-Germain-en-Laye, France). Resistant clones were selected with hygromycin (300 mg/ml, Clontech) and protein expression was checked after doxycycline treatment (1 mg/ml). NFAT5 exon 5 with 245 and 173 bp of flanking introns was amplified by PCR with primers containing NdeI restriction site: NFAT5_in4S (GGAATTCC ATATGGAATTCCCTACCACTTCCAGC) and NFAT5_ in5AS (GGAATTCCATATGGAATTCCTTTATTGCCTCA GC). NdeI-digested PCR product was cloned into pTB minigene. Primers used for minigene assay are: pTBalpha (CAACTTCAAGCTCCTAAGCCACTGC) and pTBbra (GGTCACCAGGAAGTTGGTTAAATCA).
Cell transfection
Cells were transiently transfected with siRNAs (Table 1) at a final concentration of 26.6 nM (except in Figure 3d , 10 nM siddx5/17 and 20 nM siN5) using RNAiMax (Invitrogen, Carlsbad, CA, USA). Cells were harvested 48 h after transfection. Transfections were performed using Lipofectamine LTX (Invitrogen) in immunoprecipitation and minigene assays. HeLa cells were plated and transfected with siRNAs targeting ddx5 and ddx17 UTRs and transfected 24 h later with siRNAs and expression vectors using Lipofectamine 2000 (Invitrogen) in rescue experiments.
RNA, RT-PCR and RT-qPCR
Total RNAs were extracted using TRIzol (Invitrogen). 1 ml of Glycoblue (Ambion/Applied Biosystems, Austin, TX, USA) was added before RNA precipitation with isopropanol. RNAs (1 mg) were treated with DNase I (DNAfree, Ambion) 30 min at 37 1C and reverse-transcribed using SuperScript II and random primers (Invitrogen). Before performing PCR, all RT reaction mixtures were diluted to contain 2.5 ng/ml of initial RNA. PCRs were performed using 5 ml of the diluted cDNAs and GoTaq polymerase (Promega, Madison, WI, USA). qPCR was performed using 2.5 ml of the diluted cDNAs and SYBR Green I Master mix on a LightCycler (Roche, Mannheim, Germany). Primer sequences are provided in Table 1 . The relative amounts of mRNAs were determined on the basis of the threshold cycle for each PCR product (C t ) and were normalized with Actin RNA levels (CCTCCCTGG AGAAGAGCTA; CCAGACAGCACTGTGTTGG). Primers used to analyze S100A4 and LCN2 were: S100A4-E2S (GATG TGATGGTGTCCACCTTC);S100A4-E3AS (GTACTCTTG GAAGTCCACCTC); LCN2-E2S (GGTAGGCCTGGCAGGG AATG); LCN2-E3AS (CTTAATGTTGCCCAGCGTGAAC). Primers used to analyze NFAT5 splicing were: NFAT5-E3S2 (AATGAGTCAGACAAGCGGTG) and . Primers used to analyze UPF1 were: UPF1-S (ACACCAAGCTCTACCAGGAGG) and UPF1-AS (ACAATGATGACGCCATACCTTG). Co-immunoprecipitation MDA-MB-231 cells were lysed 24 h after transfection in buffer containing 50 mM Tris-HCl pH 8, 150 mM NaCl, 1% NP40, 1 mM PMSF, protease and phosphatase inhibitors (Sigma). Cleared cell extracts were incubated overnight with 4 mg of antibodies bound to protein G magnetic beads (Invitrogen). The protein-bound magnetic beads were washed three times with PBS1X, resuspended in loading buffer before WB analysis. Inputs correspond to 5% volume of the cleared cell lysates.
In situ PLA The in situ PLA was conducted using the Duolink II Kit (Olink Bioscience, Uppsala, Sweden) according to the manufacturer's instructions. Proximity ligation signals were detected with a Zeiss fluorescence microscope (63 Â objective) and images were processed with ImageJ software program.
Luciferase assay
The osmotic stress-responsive luciferase reporter plasmid ORE Luc, which incorporates 132 bp of the human aldose reductase gene enhancer containing three consensus binding sites for NFAT5, was made by PCR amplifying genomic DNA (5 0 -TTACATGGAAAAATATCTGGGCTAG-3 0 ; 5 0 -CTGGTAG TGACTCAAGCAC-3 0 ) and cloning the resulting PCR fragment 5 0 of the minimal SV40 promoter in the luciferase reporter plasmid pGL3 (Promega) (Lopez-Rodriguez et al.,
2001
). MDA-MB-231 were plated in 10-cm plates and transfected with firefly luciferase reporter gene (3 mg), renilla luciferase control plasmid (100 ng), NFAT5 (4 mg), ddx5 and ddx17 expression vectors (2 mg). After 24 h, cells were plated in 6-well plates in triplicates. Harvested cells were lysed with lysis buffer 5X to measure firefly and renilla luciferase activities using Dual Luciferase Reporter Assay System (Promega).
ChIP and RNA-ChIP Cells were cross-linked with 1% formaldehyde for 10 min and lysed in buffer containing 50 mM Tris-HCl pH 7.5, 150 mM KCl, 5 mM EDTA, 1% NP40, 0.1% SDS, 0.5% sodium deoxycholate, 50 mM sodium fluoride, phosphatase and protease inhibitors. Chromatin was sheared by sonication with Bioruptor (Diagenode, Lie`ge, Belgium) to generate B200-bp DNA fragments and incubated with antibodies and magnetic beads overnight at 4 1C. Beads were washed five times with buffer containing 50 mM Tris-HCl pH7.5, 150 mM KCl, 1% NP40 and 0.25% sodium deoxycholate, and two times with TE buffer. Antibody-bound chromatin was reversecrosslinked overnight at 65 1C and treated with proteinase K (Qiagen, Valencia, CA, USA) before DNA purification on column (Qiagen). Purified DNA was diluted three times in water and analyzed by PCR using the following primers: hS100A4-pS1 (CAGAGTCCTGCCCTCAAGGAA); hS100A4-pAS1 (TCTCCGTGGTCATTCCCATC); hLCN2-pS1 (CCCA TGCAAGGAGGGAAATC); and LCN2-pAS1 (CCTCATGGG AGGTGGTGTTG). RNA-ChIP was performed using NFAT5-E5S2 (TTGCCTCTGAAGCAGGGAGTG) and NFAT5-I5AS (ATGCTGGTGGTCCACATTCAA) primers as previously described (Bittencourt et al., 2008) .
Migration assay
Cells were transfected with NFAT5 and b-Gal constructs (1 mg) or with siRNAs (siNFAT5, siddx5/17, siddx5, siddx17). Migration assay was performed as previously described (Jauliac et al., 2002) . Regulation of NFAT5 by ddx5/ddx17 S Germann et al
